• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FCGR3A Gene Record

  • Summary
  • Interactions
  • Claims
  • FCGR3A 2214 Druggable Genome

    Alternate Names:

    2214
    FC FRAGMENT OF IGG RECEPTOR IIIA
    FCGR3A
    CD16
    CD16A
    FCG3
    FCGR3
    FCGRIII
    FCR-10
    FCRIII
    FCRIIIA
    IGFR3
    IMD20
    146740
    3619
    ENSG00000203747
    OTTHUMG00000034466
    PA28065
    P08637
    BE0002097
    Immunoglobulin gamma Fc receptor IIIA
    T59001
    3017
    NM_000569
    NP_000560

    Gene Info:

    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name CD molecules
    GuideToPharmacology Gene Category ID 852
    GuideToPharmacology Gene Category Name Immunoglobulin like domain containing proteins
    GuideToPharmacology Gene Category ID 984
    (5 More Sources)

    Gene Categories: Category Details

    EXTERNAL SIDE OF PLASMA MEMBRANE
    DRUGGABLE GENOME

    Publications:

    Negri FV et al., 2014, Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy., Pharmacogenomics J
    Morgen EK et al., 2017, Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis., Pharmacogenomics J
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Zhang et al., 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab., J. Clin. Oncol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Magnes T et al., 2018, The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab., Pharmacogenomics J
    Shepshelovich D et al., 2018, Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer., Cancer Med
    Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
    Fujita et al., 2007, Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil., Intern. Med.
    Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
    Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
    Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
    Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
    Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
    Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
    Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
    Varchetta et al., 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2., Cancer Res.
    Musolino A et al., 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer., J Clin Oncol
    Tamura K et al., 2011, FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer., Ann Oncol
    Suzuki et al., 2007, A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients., Clin. Cancer Res.
    Lin et al., 2005, FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia., Blood
    Harris et al., 1989, Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor., J. Immunol.
    Smyth et al., 1991, IL-8 gene expression and production in human peripheral blood lymphocyte subsets., J. Immunol.
    Wang Y et al., 2004, Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro., Angiogenesis
    Maes et al., 2007, Comparison of sample fixation and the use of LDS-751 or anti-CD45 for leukocyte identification in mouse whole blood for flow cytometry., J. Immunol. Methods
    Nishio M et al., 2009, FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation., Eur J Haematol
    Kim SH et al., 2015, Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab., JAMA Neurol
    Hatjiharissi et al., 2007, Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy., Clin Lymphoma Myeloma
    Quartuccio L et al., 2014, The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study., Ann Rheum Dis
    Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol
    Weng WK et al., 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma., J Clin Oncol
    Niwa et al., 2004, Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism., Clin. Cancer Res.
    Kim et al., 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood
    Baj et al., 1992, T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment., Arch. Immunol. Ther. Exp. (Warsz.)
    Edwards et al., 1995, Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways., Blood
    Indraccolo et al., 1993, Standardization of in vitro synthesis and detection of HIV-1-specific antibodies., J. Immunol. Methods
    László et al., 2001, Increased histidine decarboxylase expression during in vitro monocyte maturation; a possible role of endogenously synthesised histamine in monocyte/macrophage differentiation., Inflamm. Res.
    Paciucci et al., 1991, Immunotherapy with IL2 by constant infusion and weekly doxorubicin., Am. J. Clin. Oncol.
    Schomburg et al., 1992, Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma., Mol. Biother.
    Takahashi et al., 2007, Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells., Scand. J. Immunol.
    Tsukahara S et al., 2008, A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis., Ann Rheum Dis
    Montes A et al., 2015, FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors., Pharmacogenomics
    Hiatt A et al., 2014, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy., Proc Natl Acad Sci U S A
    Yeager et al., 2002, Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans., Anesth. Analg.
    Vendemiale et al., 1992, Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results., Arzneimittelforschung
    Vaishnaw et al., 2002, Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration., J Pharmacokinet Pharmacodyn
    da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.
    Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
    Laviolette M et al., 2013, Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia., J Allergy Clin Immunol
    Wang B et al., 2017, Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma., CPT Pharmacometrics Syst Pharmacol
    Ghazi A et al., 2012, Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma., Expert Opin Biol Ther
    Seimetz D et al., 2010, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy., Cancer Treat Rev
  • TESMILIFENE HYDROCHLORIDE   FCGR3A

    Interaction Score: 3.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11556524


    Sources:
    NCI

  • BENRALIZUMAB   FCGR3A

    Interaction Score: 2.37

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    23866823 28109128 22136436


    Sources:
    DrugBank

  • ALEFACEPT   FCGR3A

    Interaction Score: 2.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12795239 11970990 17139284 17016423


    Sources:
    DrugBank

  • RITUXIMAB   FCGR3A

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19018870 26167726 17324336 23505228 30457672 12975461 15448014 16609067


    Sources:
    PharmGKB

  • LACTULOSE   FCGR3A

    Interaction Score: 0.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1418064


    Sources:
    NCI

  • PALIVIZUMAB   FCGR3A

    Interaction Score: 0.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423 24711420


    Sources:
    DrugBank

  • TOCILIZUMAB   FCGR3A

    Interaction Score: 0.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30457672


    Sources:
    PharmGKB

  • MAFOSFAMIDE   FCGR3A

    Interaction Score: 0.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1515095


    Sources:
    NCI

  • PENICILLIN G POTASSIUM   FCGR3A

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17257217


    Sources:
    NCI

  • ETANERCEPT   FCGR3A

    Interaction Score: 0.57

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    15526004 27463856 19128982 15457442 24048425 27044681


    Sources:
    PharmGKB DrugBank

  • ADALIMUMAB   FCGR3A

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423 24048425 27044681


    Sources:
    PharmGKB

  • CATUMAXOMAB   FCGR3A

    Interaction Score: 0.44

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    20347527


    Sources:
    DrugBank

  • INFLIXIMAB   FCGR3A

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19005160 25823782 24048425 27044681


    Sources:
    PharmGKB

  • ALEMTUZUMAB   FCGR3A

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15217834


    Sources:
    DrugBank

  • TRASTUZUMAB   FCGR3A

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18089830 18347005 21109570 17363544


    Sources:
    NCI PharmGKB

  • DACLIZUMAB   FCGR3A

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • CETUXIMAB   FCGR3A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23296156 27897268 17139284 17704420 17016423 28719596 30318772


    Sources:
    NCI PharmGKB DrugBank

  • SARILUMAB   FCGR3A

    Interaction Score: 0.3

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • CIMETIDINE   FCGR3A

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11556524


    Sources:
    NCI

  • SODIUM CHLORIDE   FCGR3A

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17187818


    Sources:
    NCI

  • GELDANAMYCIN   FCGR3A

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7662976


    Sources:
    NCI

  • ALDESLEUKIN   FCGR3A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2528593 1827816


    Sources:
    NCI

  • EPOETIN ALFA   FCGR3A

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1300984


    Sources:
    NCI

  • PUROMYCIN   FCGR3A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8423352


    Sources:
    NCI

  • BEVACIZUMAB   FCGR3A

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423 15886877


    Sources:
    DrugBank

  • PREDNISOLONE   FCGR3A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17329922


    Sources:
    NCI

  • FENTANYL   FCGR3A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11772808


    Sources:
    NCI

  • THALIDOMIDE   FCGR3A

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15457133


    Sources:
    NCI

  • HEPARIN   FCGR3A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18492254


    Sources:
    NCI

  • INDOMETHACIN   FCGR3A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17329922


    Sources:
    NCI

  • CYCLOSPORINE   FCGR3A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17852453


    Sources:
    NCI

  • DOXORUBICIN   FCGR3A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1830717


    Sources:
    NCI

  • Ensembl: ENSG00000203747

    • Version: 101_38

    Alternate Names:
    FCGR3A Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • GuideToPharmacology: 2214

    • Version: 29-September-2020

    Alternate Names:
    3619 HUGO Gene ID
    3619 HUGO Gene Symbol
    Fc fragment of IgG receptor IIIa HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name CD molecules
    GuideToPharmacology Gene Category ID 852
    GuideToPharmacology Gene Category Name Immunoglobulin like domain containing proteins

    Publications:

  • PharmGKB: FCGR3A

    • Version: 18-August-2020

    Alternate Names:
    PA28065 PharmGKB ID

    Gene Info:

    Publications:
    Nishio M et al., 2009, FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation., Eur J Haematol
    Kim SH et al., 2015, Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab., JAMA Neurol
    Quartuccio L et al., 2014, The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study., Ann Rheum Dis

  • DrugBank: BE0002097

    • Version: 5.1.7

    Alternate Names:
    FCGR3A DrugBank Gene Name
    P08637 UniProt Accession
    2214 Entrez Gene Id

    Gene Info:

    Publications:
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Zhang et al., 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab., J. Clin. Oncol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

  • NCI: FCGR3A

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
    Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
    Varchetta et al., 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2., Cancer Res.

  • HingoraniCasas: ENSG00000203747

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000203747 Gene Symbol
    FCGR3A Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: FCGR3A

    • Version: 05-September-2020

    Alternate Names:
    CD16A GO Gene Synonym
    FCG3 GO Gene Synonym
    FCGR3 GO Gene Synonym

    Gene Info:

    Gene Categories:
    EXTERNAL SIDE OF PLASMA MEMBRANE

    Publications:

  • Tempus: FCGR3A

    • Version: 11-November-2018

    Alternate Names:
    FCGR3A Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Immunoglobulin gamma Fc receptor IIIA

    • Version: 2020.06.01

    Alternate Names:
    FCGR3A TTD Gene Abbreviation
    T59001 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21